Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Giannini, Marta ^a   Portaccio, Emilio ^a,m   Ghezzi, Angelo ^b   Hakiki, Bahia ^a,m   Pastò, Luisa ^a   Razzolini, Lorenzo ^a,m   Piscolla, Elisa ^a   De Giglio, Laura ^c   Pozzilli, Carlo ^c   Paolicelli, Damiano ^d   Trojano, Maria ^d   Marrosu, Maria G ^e   Patti, Francesco ^f   La Mantia, Loredana ^g   Mancardi, Gianluigi ^h   Solaro, Claudio ⁱ   Totaro, Rocco ^j   Tola, Maria R ^k   De Luca, Giovanna ^k   Lugaresi, Alessandra ^k   Moiola, Lucia ^l   Martinelli, Vittorio ^l   Comi, Giancarlo ^l   Amato, Maria P ^a   more..

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g DEPARTMENT OF NEUROSURGERY   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ Department of Neurology ^*  (Italy)

^j UNIVERSITY OF L'AQUILA   (Italy)

^k UNIVERSITY OF FERRARA   (Italy)

^l SAN RAFFAELE HOSPITAL   (Italy)

^m IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

more..

Author keywords

Glatiramer acetate; In utero exposure; Multiple sclerosis; Pregnancy; Pregnancy outcome

Indexed keywords

GLATIRAMER;

ADULT; ARTICLE; BIRTH WEIGHT; CESAREAN SECTION; CLINICAL ASSESSMENT; CONCEPTION; ENVIRONMENTAL EXPOSURE; FEMALE; FETUS OUTCOME; FOLLOW UP; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; PREMATURE LABOR; PROSPECTIVE STUDY; SPONTANEOUS ABORTION;

ADULT; COMORBIDITY; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; ITALY; MALE; MULTIPLE SCLEROSIS; PEPTIDES; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84867657238     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-124     Document Type: Article

References (16)

1. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 2010, 75:1794-1802. 10.1212/WNL.0b013e3181fd62bb, 21079181.
2. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011, 17:423-430. 10.1177/1352458510394610, 21220368.
3. Finkelsztejn A, Brooks JB, Paschoal FM, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 2011, 118:790-797. 10.1111/j.1471-0528.2011.02931.x, 21401856.
4. Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg 2012,
5. Chard T. Interferon in pregnancy. J Dev Physiol 1989, 11:271-276.
6. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009, 15:1037-1042. 10.1177/1352458509106543, 19692433.
7. Coyle PK, Johnson K, Pardo L, Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003, 60:A60.
8. Fragoso YD, Finkelsztejn A, Comini-Frota ER, et al. Pregnancy and multiple sclerosis: the initial results from a Brazilian database. Arq Neuropsiquiatr 2009, 67:657-660. 10.1590/S0004-282X2009000400015, 19722044.
9. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol 2010, 257:2020-2023. 10.1007/s00415-010-5652-y, 20625758.
10. Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs 2010, 24:969-976.
11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127. 10.1002/ana.1032, 11456302.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452. 10.1212/WNL.33.11.1444, 6685237.
13. Raghupathy R, Kalinka J. Cytokine imbalance in pregnancy complications and its modulation. Front Biosci 2008, 13:985-994. 10.2741/2737, 17981605.
14. Challier JC, Guerre-Millo M, Nandakumaran M, Gerbaut L. d'Athis P. Clearance of compounds of different molecular size in the human placenta in vitro. Biol Neonate 1985, 48:143-148. 10.1159/000242165, 2413911.
15. Waysbort A, Giroux M, Mansat V, Teixeira M, Dumas JC, Puel J. Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrob Agents Chemother 1993, 37:1232-1237. 10.1128/AAC.37.6.1232, 187945, 8328774.
16. Putheti P, Soderstrom M, Link H, Huang YM. Effect of glatiramer acetate (Copaxone) on CD4 + CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol 2003, 144:125-131. 10.1016/j.jneuroim.2003.08.001, 14597106.